BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32857656)

  • 21. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes.
    Racsa PN; Meah Y; Ellis JJ; Saverno KR
    J Manag Care Spec Pharm; 2017 Mar; 23(3):291-298. PubMed ID: 28230457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes.
    Perez-Nieves M; Boye KS; Kiljanski J; Cao D; Lage MJ
    Diabetes Ther; 2018 Jun; 9(3):1099-1111. PubMed ID: 29644618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.
    Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD
    BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benchmarking Insulin Treatment Persistence Among Patients with Type 2 Diabetes Across Different U.S. Payer Segments.
    Wei W; Jiang J; Lou Y; Ganguli S; Matusik MS
    J Manag Care Spec Pharm; 2017 Mar; 23(3):278-290. PubMed ID: 28230445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 29. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.
    Ye X; Qian C; Liu J; St Peter WL
    Pharmacotherapy; 2013 Oct; 33(10):1062-70. PubMed ID: 23798059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medication adherence and improved outcomes among patients with type 2 diabetes.
    Curtis SE; Boye KS; Lage MJ; Garcia-Perez LE
    Am J Manag Care; 2017 Jul; 23(7):e208-e214. PubMed ID: 28850793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
    Dalal MR; Kazemi M; Ye F; Xie L
    Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
    Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C
    J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242
    [No Abstract]   [Full Text] [Related]  

  • 34. Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States.
    Joish VN; Zhou FL; Preblick R; Lin D; Deshpande M; Verma S; Davies MJ; Paranjape S; Pettus J
    J Manag Care Spec Pharm; 2020 Mar; 26(3):311-318. PubMed ID: 32105172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.